204 related articles for article (PubMed ID: 25986146)
1. Ivabradine prolongs phase 3 of cardiac repolarization and blocks the hERG1 (KCNH2) current over a concentration-range overlapping with that required to block HCN4.
Lees-Miller JP; Guo J; Wang Y; Perissinotti LL; Noskov SY; Duff HJ
J Mol Cell Cardiol; 2015 Aug; 85():71-8. PubMed ID: 25986146
[TBL] [Abstract][Full Text] [Related]
2. hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.
Melgari D; Brack KE; Zhang C; Zhang Y; El Harchi A; Mitcheson JS; Dempsey CE; Ng GA; Hancox JC
J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25911606
[TBL] [Abstract][Full Text] [Related]
3. In response to Melgari et al. "hERG potassium channel inhibition by ivabradine requires channel gating".
Lees-Miller JP; Guo J; Wang Y; Perissinotti LL; Noskov SY; Duff HJ
J Mol Cell Cardiol; 2015 Oct; 87():192-3. PubMed ID: 26299838
[No Abstract] [Full Text] [Related]
4. The Pore-Lipid Interface: Role of Amino-Acid Determinants of Lipophilic Access by Ivabradine to the hERG1 Pore Domain.
Perissinotti L; Guo J; Kudaibergenova M; Lees-Miller J; Ol'khovich M; Sharapova A; Perlovich GL; Muruve DA; Gerull B; Noskov SY; Duff HJ
Mol Pharmacol; 2019 Aug; 96(2):259-271. PubMed ID: 31182542
[TBL] [Abstract][Full Text] [Related]
5. hERG potassium channel inhibition by ivabradine requires channel gating.
Melgari D; Brack KE; Zhang Y; El Harchi A; Mitcheson JS; Dempsey CE; Ng GA; Hancox JC
J Mol Cell Cardiol; 2015 Oct; 87():126-8. PubMed ID: 26275355
[No Abstract] [Full Text] [Related]
6. Molecular interaction of droperidol with human ether-a-go-go-related gene channels: prolongation of action potential duration without inducing early afterdepolarization.
Schwoerer AP; Blütner C; Brandt S; Binder S; Siebrands CC; Ehmke H; Friederich P
Anesthesiology; 2007 May; 106(5):967-76. PubMed ID: 17457128
[TBL] [Abstract][Full Text] [Related]
7. Identification of the molecular site of ivabradine binding to HCN4 channels.
Bucchi A; Baruscotti M; Nardini M; Barbuti A; Micheloni S; Bolognesi M; DiFrancesco D
PLoS One; 2013; 8(1):e53132. PubMed ID: 23308150
[TBL] [Abstract][Full Text] [Related]
8. Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels.
Bucchi A; Tognati A; Milanesi R; Baruscotti M; DiFrancesco D
J Physiol; 2006 Apr; 572(Pt 2):335-46. PubMed ID: 16484306
[TBL] [Abstract][Full Text] [Related]
9. Block of hERG K+ channel and prolongation of action potential duration by fluphenazine at submicromolar concentration.
Hong HK; Lee BH; Park MH; Lee SH; Chu D; Kim WJ; Choe H; Hee Choi B; Jo SH
Eur J Pharmacol; 2013 Feb; 702(1-3):165-73. PubMed ID: 23395964
[TBL] [Abstract][Full Text] [Related]
10. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
[TBL] [Abstract][Full Text] [Related]
11. H(1) antihistamine drug promethazine directly blocks hERG K(+) channel.
Jo SH; Hong HK; Chong SH; Lee HS; Choe H
Pharmacol Res; 2009 Nov; 60(5):429-37. PubMed ID: 19497368
[TBL] [Abstract][Full Text] [Related]
12. The funny current: cellular basis for the control of heart rate.
DiFrancesco D; Borer JS
Drugs; 2007; 67 Suppl 2():15-24. PubMed ID: 17999560
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules.
Schmidtke P; Ciantar M; Theret I; Ducrot P
J Chem Inf Model; 2014 Aug; 54(8):2320-33. PubMed ID: 25000969
[TBL] [Abstract][Full Text] [Related]
14. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
Durdagi S; Duff HJ; Noskov SY
J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
[TBL] [Abstract][Full Text] [Related]
15. Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel.
Ridley JM; Milnes JT; Hancox JC; Witchel HJ
J Mol Cell Cardiol; 2006 Jan; 40(1):107-18. PubMed ID: 16288909
[TBL] [Abstract][Full Text] [Related]
16. Block of hERG channel by ziprasidone: biophysical properties and molecular determinants.
Su Z; Chen J; Martin RL; McDermott JS; Cox BF; Gopalakrishnan M; Gintant GA
Biochem Pharmacol; 2006 Jan; 71(3):278-86. PubMed ID: 16325148
[TBL] [Abstract][Full Text] [Related]
17. Blockade of HERG cardiac K+ current by antifungal drug miconazole.
Kikuchi K; Nagatomo T; Abe H; Kawakami K; Duff HJ; Makielski JC; January CT; Nakashima Y
Br J Pharmacol; 2005 Mar; 144(6):840-8. PubMed ID: 15778703
[TBL] [Abstract][Full Text] [Related]
18. The human ether-a-go-go-related gene (hERG) current inhibition selectively prolongs action potential of midmyocardial cells to augment transmural dispersion.
Yasuda C; Yasuda S; Yamashita H; Okada J; Hisada T; Sugiura S
J Physiol Pharmacol; 2015 Aug; 66(4):599-607. PubMed ID: 26348084
[TBL] [Abstract][Full Text] [Related]
19. Increased cardiac risk in concomitant methadone and diazepam treatment: pharmacodynamic interactions in cardiac ion channels.
Kuryshev YA; Bruening-Wright A; Brown AM; Kirsch GE
J Cardiovasc Pharmacol; 2010 Oct; 56(4):420-30. PubMed ID: 20930594
[TBL] [Abstract][Full Text] [Related]
20. The molecular determinants of R-roscovitine block of hERG channels.
Cernuda B; Fernandes CT; Allam SM; Orzillo M; Suppa G; Chia Chang Z; Athanasopoulos D; Buraei Z
PLoS One; 2019; 14(9):e0217733. PubMed ID: 31479461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
